Goldman Sachs Group Inc Eliem Therapeutics, Inc. Transaction History
Goldman Sachs Group Inc
- $596 Billion
- Q1 2025
A detailed history of Goldman Sachs Group Inc transactions in Eliem Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 120,742 shares of ELYM stock, worth $496,249. This represents 0.0% of its overall portfolio holdings.
Number of Shares
120,742
Previous 120,742
-0.0%
Holding current value
$496,249
Previous $496,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding ELYM
# of Institutions
73Shares Held
49.8MCall Options Held
0Put Options Held
0-
Ra Capital Management, L.P. Boston, MA31.4MShares$129 Million2.68% of portfolio
-
Cantor Fitzgerald, L. P. New York, NY2MShares$8.22 Million0.18% of portfolio
-
Citigroup Inc1.85MShares$7.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.5MShares$6.18 Million0.0% of portfolio
-
Affinity Asset Advisors, LLC New York, NY1.5MShares$6.17 Million0.69% of portfolio
About Eliem Therapeutics, Inc.
- Ticker ELYM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,567,700
- Market Cap $109M
- Description
- Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase II...